Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium adolescentis CCDM 368
- Development stage
- Preclinical
- Lead developer
- Institute of Immunology and Experimental Therapy
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intranasal, Oral
01
Overview
Bifidobacterium adolescentis CCDM 368 is a research-stage probiotic bacterial strain isolated from the fecal samples of healthy human adults. It is maintained by the Czech Collection of Dairy Microorganisms (CCDM). The strain and its surface-derived components, particularly the exopolysaccharide Bad368.1 PS (also known as BAP1), are being investigated for their immunomodulatory and anti-allergic properties. In preclinical models of ovalbumin-induced airway allergy, intranasal administration of BAP1 has been shown to attenuate allergic inflammation, reduce eosinophil infiltration in bronchoalveolar lavage fluid, and modulate cytokine production by inhibiting Th2-related pathways (such as IL-4, IL-5, and IL-13) while promoting Th1-related responses (such as IFN-gamma). Additionally, the live bacterium has been studied ex vivo for its potential inhibitory effects on platelet activation pathways (COX-1, ADP, and TRAP-6) in patients with aneurysmal subarachnoid hemorrhage.
- Other names
- Bad 368Bad368Bad-368Bifidobacterium adolescentis strain CCDM 368CCDM 368CCDM368CCDM-368
02
Targets
CCL2 (C-C motif chemokine 2)PGHS-1 (Prostaglandin G/H Synthase 1)IFNG (Interferon gamma)IL-13 (Interleukin-13)IL-4 (Interleukin 4)IL-5 (Interleukin 5)PRR (Pattern recognition receptors)F2R (Protease-activated receptor 1)RORC (Retinoic acid receptor-related orphan receptor gamma)
Beyond the preview
Go deeper on Bifidobacterium adolescentis CCDM 368.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium adolescentis CCDM 368.